| 0.1053 -0.063 (-37.43%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
NanoString Technologies, Inc. is a global innovator in scientific instrumentation, designing and producing advanced research tools for genomics and proteomics across the Americas, Europe, the Middle East, and Asia Pacific. Its flagship offering is the nCounter Analysis System, an automated platform renowned for its versatile digital detection and counting capabilities. This system includes both nCounter MAX and FLEX configurations, which integrate a Prep Station for automated liquid handling and sample preparation, alongside a Digital Analyzer. The Analyzer captures data by imaging fluorescent reporters within sample cartridges, then processes this information into usable output files. The company also offers the nCounter SPRINT Profiler, a compact instrument that streamlines liquid handling and digital analysis using a specialized microfluidic cartridge. Complementing its hardware, NanoString provides nSolver Analysis Software, a powerful program enabling researchers to verify, normalize, and interpret their experimental data. Further extending its product portfolio, NanoString supplies customizable CodeSets and pre-designed panels tailored for applications in oncology, immunology, infectious diseases, and neuroscience. Essential Master Kits, containing reagents and plasticware, are also available to facilitate sample setup and processing within their nCounter Prep Station and Digital Analyzer. Additionally, they market Prosigna molecular diagnostic test kits. Looking ahead, NanoString is actively developing the GeoMx DSP system, poised to advance the field of spatial genomics. The company maintains strategic partnerships, including collaborations with Lam Research Corporation for the research and development of Hyb & Seq technologies, and with Celgene Corporation on LymphMark, an in vitro diagnostic for diffuse large B-cell lymphoma. They also work with the Parker Institute for Cancer Immunotherapy to improve CAR-T regimens and patient outcomes across various cancer types. Established in 2003, NanoString Technologies, Inc. operates from its headquarters in Seattle, Washington.
Tue, 28 May 2024
NanoString Technologies, Inc. has Changed its Name to NS Wind Down Co., Inc - marketscreener.com
Sun, 11 Feb 2024
NanoString Technologies secures $47.5M in bankruptcy financing - The Business Journals
Sun, 07 Jan 2024
NanoString’s CosMx SMI Achieves Whole Transcriptome Imaging at Single-Cell Resolution - Business Wire
Fri, 17 Nov 2023
10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies - PR Newswire
Tue, 13 Dec 2022
NanoString’s CosMx Spatial Molecular Imager Recognized by The Scientist Magazine as a Top 10 Innovation of 2022 - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|